Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Doravirine

FDA-approved product (tablet, oral), marketed as Pifeltro.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Doravirine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Doravirine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doravirine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)

    NCT02549040 · start 2015-09-21

    Registered record
    Registry ID
    NCT02549040
    Conditions
    Human Immunodeficiency Virus-1 (HIV-1)
    Interventions
    Treatment A: Doravirine 100 mg film coated tablet; Treatment B: Doravirine 150 mg tablet (40% drug loaded granule); Treatment C: Doravirine 150 mg tablet (30% drug loaded granule); Treatment D: Doravirine 150 mg tablet (50% drug loaded granule); Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-09-21
    Completion
    2015-12-24
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus-1 (HIV-1)
    InterventionTreatment A: Doravirine 100 mg film coated tablet; Treatment B: Doravirine 150 mg tablet (40% drug loaded granule); Treatment C: Doravirine 150 mg tablet (30% drug loaded granule); Treatment D: Doravirine 150 mg tablet (50% drug loaded granule) +1 more
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)

    NCT02397096 · start 2015-06-09

    Registered record
    Registry ID
    NCT02397096
    Conditions
    HIV-1 Infection
    Interventions
    Doravirine, Tenofovir, Lamivudine; Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor; Baseline regimen of cobicistat-boosted elvitegravir; Baseline regimen of a non-nucleoside reverse transcriptase inhibitor; Baseline regimen of two nucleoside reverse transcriptase inhibitors
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-06-09
    Completion
    2023-09-05
    Enrolment
    673

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionDoravirine, Tenofovir, Lamivudine; Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor; Baseline regimen of cobicistat-boosted elvitegravir; Baseline regimen of a non-nucleoside reverse transcriptase inhibitor +1 more
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

    NCT02275780 · start 2014-12-01

    Registered record
    Registry ID
    NCT02275780
    Conditions
    HIV-1
    Interventions
    Doravirine; Darunavir; Ritonavir; TRUVADA™ or EPZICOM™/KIVEXA™
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12-01
    Completion
    2023-03-06
    Enrolment
    769

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionDoravirine; Darunavir; Ritonavir; TRUVADA™ or EPZICOM™/KIVEXA™
    PhasePhase 3
    Registry statusCompleted

  • A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)

    NCT02089659 · start 2014-03-26

    Registered record
    Registry ID
    NCT02089659
    Conditions
    HIV-1 Infection
    Interventions
    Doravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-03-26
    Completion
    2014-05-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionDoravirine
    PhasePhase 1
    Registry statusCompleted

  • A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)

    NCT01466985 · start 2011-10-21

    Registered record
    Registry ID
    NCT01466985
    Conditions
    HIV-1 Infection
    Interventions
    Doravirine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-10-21
    Completion
    2012-04-10
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionDoravirine; Placebo
    PhasePhase 1
    Registry statusCompleted